soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
Company profile
Ticker
SLNO
Exchange
Website
CEO
Anish Bhatnagar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
Capnia, Inc.
SEC CIK
Corporate docs
Subsidiaries
Soleno Therapeutics U.K. Ltd. • Soleno Therapeutics Europe Ltd. • Essentialis, Inc. ...
SLNO stock data
Latest filings (excl ownership)
8-K
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
7 May 24
424B5
Prospectus supplement for primary offering
6 May 24
424B5
Prospectus supplement for primary offering
2 May 24
8-K
First Ever Breakthrough Designation for a Drug Being Developed for PWS
29 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Departure of Directors or Certain Officers
22 Apr 24
8-K
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7 Mar 24
Latest ownership filings
4
Change in insider ownership
1 May 24
SC 13D/A
Vivo Opportunity Fund Holdings, L.P.
1 May 24
3
Meredith Manning
30 Apr 24
3
Michael F. Huang
30 Apr 24
4
Kristen Yen
3 Apr 24
4
James H Mackaness
3 Apr 24
4
Patricia C Hirano
3 Apr 24
4
Bhatnagar Anish
3 Apr 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.44 mm | 52.44 mm | 52.44 mm | 52.44 mm | 52.44 mm | 52.44 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.46 mm | 2.76 mm | 2.11 mm | 1.98 mm |
Cash used (since last report) | n/a | n/a | 25.46 mm | 20.28 mm | 15.53 mm | 14.57 mm |
Cash remaining | n/a | n/a | 26.97 mm | 32.15 mm | 36.91 mm | 37.86 mm |
Runway (months of cash) | n/a | n/a | 7.8 | 11.7 | 17.5 | 19.1 |
Institutional ownership, Q4 2023
98.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 50 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 770.56 mm |
Total shares | 32.75 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Jack W. Schuler Living Trust | 11.91 mm | $35.02 mm |
Vivo Opportunity Fund | 8.42 mm | $35.36 mm |
Larry N Feinberg | 3.73 mm | $7.20 mm |
Perceptive Advisors | 3.07 mm | $72.62 mm |
CG Carlyle Group Inc | 2.89 mm | $70.81 mm |
Adage Capital Partners GP, L.L.C. | 1.33 mm | $35.14 mm |
Commodore Capital | 885.74 k | $23.45 mm |
Hirschman Orin | 498.61 k | $2.80 mm |
Aspiriant | 12.13 k | $488.15 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | No | 45.13 | 351,242 | 15.85 mm | 7,316,851 |
29 Apr 24 | Vivo Opportunity | Common Stock | Sell | Dispose S | Yes | No | 47.8 | 750,000 | 35.85 mm | 7,668,093 |
1 Apr 24 | Anish Bhatnagar | Common Stock | Sell | Dispose S | No | No | 41.6671 | 7,597 | 316.54 k | 152,790 |
1 Apr 24 | Anish Bhatnagar | Common Stock | Sell | Dispose S | No | No | 41.1227 | 11,383 | 468.10 k | 160,387 |
1 Apr 24 | Hirano Patricia C | Common Stock | Sell | Dispose S | No | No | 41.6671 | 888 | 37.00 k | 50,924 |
1 Apr 24 | Hirano Patricia C | Common Stock | Sell | Dispose S | No | No | 41.1227 | 1,330 | 54.69 k | 41,812 |
News
Baird Initiates Coverage On Soleno Therapeutics with Outperform Rating, Announces Price Target of $72
10 May 24
Soleno Therapeutics Q1 2024 Adj EPS $(0.59) Misses $(0.37) Estimate
9 May 24
Reported Earlier, Soleno Therapeutics Prices $138M Public Offering Of 3M Common Stock At $46/Share
3 May 24
Soleno Therapeutics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
2 May 24
Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing DCCR Treatment To The Natural History Of Prader-Willi Syndrome
30 Apr 24
Press releases
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
2 May 24
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
2 May 24
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Apr 24
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24